Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Rheumatology (Oxford, England)|June 11, 2020
An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritisJean-Pierre Pelletier, Jean-Pierre Raynauld, Marc Dorais, et al.
Clinical and Experimental Rheumatology|January 9, 2019
Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohortValerie Nadon, Anna Moltó, Adrien Etcheto, et al.
Seminars in Arthritis and Rheumatism|February 6, 2010
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritisJean-Pierre Raynauld, Johanne Martel-Pelletier, André Beaulieu, et al.
Arthritis and Rheumatism|March 13, 2003
Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trialSimon Carette, Hélène Moffet, Johanne Tardif, et al.
Annals of the Rheumatic Diseases|March 4, 2011
Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRILukas Martin Wildi, Jean-Pierre Raynauld, Johanne Martel-Pelletier, et al.
Patient Preference and Adherence|June 30, 2025
Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational StudyLouis Bessette, Pauline Boulos, Regan Arendse, et al.
Arthritis Research & Therapy|April 29, 2023
Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?Walter P Maksymowych, Robert D Inman, Louis Bessette, et al.
The Journal of Rheumatology|June 1, 2023
Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 MonthsLouis Bessette, Proton Rahman, John Kelsall, et al.
Rheumatology and Therapy|April 11, 2018
Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION StudyLouis Bessette, Gerald Lebovic, Brad Millson, et al.
Seminars in Arthritis and Rheumatism|April 8, 2020
Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration studyThomas J Schnitzer, Arifulla Khan, Louis Bessette, et al.
Pageof 12